Roth sees potential fourth-quarter pivotal trial starts, adding upcoming milestones to NeOnc’s expanding analyst coverage
September 24, 2026 www.wallsreet-pr.com New analyst coverage is putting NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) and its next potential milestones in focus. Roth Capital analyst Jonathan Aschoff has initiated coverage with a Buy rating, anticipating an October FDA meeting for NEO100 and potential pivotal trial starts before year-end.
Roth’s initiation follows earlier coverage initiations from Alliance Global Partners, Maxim and BTIG, expanding the research available to investors evaluating NeOnc’s clinical progress and development strategy.
The next potential catalyst: greater clarity on the regulatory path. Published summaries of Roth’s research indicate that Aschoff anticipates an FDA Type B end-of-Phase 2 meeting for NEO100 in October. That discussion could help clarify the requirements for the program’s next stage of clinical development.
Roth also sees pivotal trials potentially beginning by the end of 2026. Looking further ahead, the firm model’s possible commercial launches for NEO100 in 2029 and NEO212 in 2030.
Roth’s outlook extends beyond the next regulatory milestone to potential commercialization. Published summaries of its research indicate that the firm models NEO100 and NEO212 launches in 2029 and 2030, respectively, and projects $667 million in operating income for 2033. Its discounted cash-flow valuation uses a 20% discount rate and a five-times multiple of that projected operating income. These forecasts depend on successful clinical development, regulatory approval, financing and commercial execution.
These milestones represent analyst expectations, rather than confirmed regulatory outcomes or guaranteed timelines. Progress will depend on FDA feedback, additional clinical evidence and sufficient financing.
The initiation follows NeOnc’s announcement of positive topline Phase 2a results for NEO100. Alongside its NEO212 program, the company is pursuing investigational treatments intended to address challenges in brain cancer and drug delivery to the central nervous system.
For investors following NTHI, the new coverage adds both another Buy recommendation and a framework for watching what comes next: regulatory clarity, trial advancement and execution.
NeOnc remains a clinical-stage company. Its investigational therapies require further development and regulatory review. Clinical outcomes, financing needs and regulatory decisions remain material risks. Analyst ratings reflect each firm’s views at the time of publication, may change and do not guarantee future performance.
About Wall Street PR
Wall Street PR (WSTPR) provides investor relations, financial communications and market commentary for public companies and investors. Through press releases, targeted distribution, email newsletters and editorial coverage, WSTPR helps companies communicate significant developments, engage shareholders and expand their market presence.
For further information, visit wallstreet-pr.com.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. WSTPR is a third-party media provider that has been compensated $1,500 for this editorial by 247 MN on behalf of the company for providing ongoing NTHI editorial market outreach and other services. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further info, visit the disclosure page.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
CONTACT:
Wall Street PR
[email protected]
